Udayavni Special

DCGI nod to Serum Institute of India for phase 2 and 3 human clinical trials of Oxford vaccine candidate


PTI, Aug 3, 2020, 8:39 AM IST

New Delhi: The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India (SII) for conducting phase 2 and 3 human clinical trials of the Oxford University developed COVID-19 vaccine candidate in the country.

Government officials told PTI that the approval for conducting phase 2 and 3 clinical trials by the SII was granted by DCGI Dr. V G Somani late Sunday night after a thorough evaluation based on the recommendations of the Subject Expert Committee (SEC) on COVID-19.

“The firm has to submit safety data, evaluated by the Data Safety Monitoring Board (DSMB), to the CDSCO before proceeding to phase 3 clinical trials,” a senior official said.

“As per the study design, each subject will be administered two doses four weeks apart (first dose on day one and second dose on day 29) following which the safety and immunogenicity will be assessed at predefined intervals,” the official said.

“As a rapid regulatory response, the expert panel at the Central Drugs Standard Control Organisation (CDSCO) on Friday, after detailed deliberation and considering the data generated on the vaccine candidate in phase 1 and 2 of the Oxford University trial, had recommended granting permission for phase 2 and 3 clinical trials of the potential vaccine, ‘Covishield’, on healthy adults in India,” the officials said.

Currently, phase 2 and 3 clinical trials of the Oxford vaccine candidate is going on in the United Kingdom, phase 3 clinical trial in Brazil, and phase 1 and 2 clinical trials in South Africa.

The officials said that the SII had submitted a revised proposal on Wednesday after the SEC on July 28, following deliberation over its application, had asked it to revise its protocol for the phase 2 and 3 clinical trials besides seeking some additional information.

The panel had also recommended that the clinical trial sites which have been proposed for the study be distributed across India.

According to the revised proposal by the SII, 1,600 people aged above 18 years will participate in the trials across 17 selected sites, including AIIMS-Delhi, B J Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh, AIIMS-Jodhpur, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysore.

“According to the application, it would conduct an observer-blind, randomized controlled study to determine the safety and immunogenicity of ‘Covishield’ on healthy Indian adults,” the official said.

The SII, which has partnered with AstraZeneca, for manufacturing the Oxford vaccine candidate for COVID-19 had submitted its first application to the DCGI on July 25 seeking permission for conducting the phase 2 and 3 trials of the potential vaccine.

Initial results of the first two-phases of trials of the vaccine conducted in five trial sites in the UK showed that it has an acceptable safety profile and homologous boosting increased antibody response, sources had said.

To introduce the vaccine, SII, the world’s largest vaccine maker by the number of doses produced and sold, has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute (Oxford University) in collaboration with British-Swedish pharma company AstraZeneca.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

India has never accepted so-called unilaterally defined 1959 Line of Actual Control: MEA

We don’t agree with what Kangana said, but is this way to react: HC to Raut

Netherlands shows interest in indigenously developed Feluda test

Mukesh Ambani’s wealth shoots up 73% to Rs 6.58 lakh crore; Adani moves up in net worth rankings

Polls in Gilgit-Baltistan attempt to camouflage illegal occupation of region by Pakistan: MEA

Kerala lab manager held for issuing ‘fake’ COVID-19 certificates to travellers

Serum Institute to produce additional 100 mn COVID-19 vaccine doses for India, other countries




Related Articles More

Single-day COVID-19 cases in India drop below 75,000, recovery rate rises to 83.01 pc

COVID-19: BJP leader Uma Bharti who tested positive admitted to AIIMS

K’taka COVID-19 update: 6892 new cases, 7509 discharges, 59 deaths on Sep 27

From elbow ‘hi’ to separate entry-exit points: How Amitabh Bachchan is shooting ‘KBC’ amid COVID-19

COVID-19 recoveries in India cross 50 lakh mark

MUST WATCH

Want to help farmers, Remove Middlemen | APMC Act Amendment ಆಗ್ಲೇ ಬೇಕು – Shiv Murthy Kota

How to Start Dairy Farm | Cow Farming Explained | Udayavani

Karnataka bandh evokes lukewarm response in Bajpe, Ujire and Belthangady

Success Story of Udupi Farmer | Satisfaction in Agriculture

Pro-farmer Organizations Protests over farm bills in BC Road And Moodbidri

Latest Additions

Edu Dept to act against institutions running tin-shed schools

United Arab Emirates to send 1st ‘Arab mission’ to moon in 2024

Plans on for development of Jog waterfalls: DC Shivakumar

India has never accepted so-called unilaterally defined 1959 Line of Actual Control: MEA

We don’t agree with what Kangana said, but is this way to react: HC to Raut

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.